Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...

US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...

When treating mild allergic reactions, allergists and pediatricians prefer children’s Zyrtec over children’s Benadryl. OTC ...

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

Climate change is affecting two value chains – beekeeping and banana juice production – that are entirely dependent on ...

Honey bees symmetrically organize nest contents, benefiting brood development and temperature control, consistent across species. Symmetry is everywhere and serves a myriad of purposes. Humans find ...

Tessa Bryant never thought she'd find herself in a bee suit - but she's now learnt all about apiary, and realised she can ...

We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...